Affymetrix and BioDiscovery Launch a Tailored Copy Number Analysis Software Solution for Cancer Research
June 05 2014 - 6:30AM
Business Wire
Affymetrix (Nasdaq: AFFX) and BioDiscovery, Inc. today announced
the launch of a new analysis software, Nexus Copy Number for
Affymetrix, which is specifically for data generated by Affymetrix’
genetic analysis platforms in cancer research, including CytoScan®
Cytogenetics Suite and OncoScan® FFPE Assay Kit.
“CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit are key
parts of our cancer portfolio,” says Dr. Andy Last, Executive Vice
President and Chief Operating Officer at Affymetrix. “Researchers
have been finding CNVs and copy neutral changes in liquid and solid
tumor samples. With the use of Nexus Copy Number, an advanced
discovery tool for interrogating large data sets, researchers have
been able to identify biomarkers that drive disease progression.
The new Nexus Copy Number for Affymetrix software offers
researchers a version of the Nexus Copy Number software that is
easier to access and has been specifically tailored for Affymetrix’
assays.”
“We are thrilled to extend our relationship with Affymetrix
through this unique product,” said Dr. Soheil Shams, BioDiscovery’s
Chief Scientific Officer. “The high quality data from the
Affymetrix assays performs extremely well in our software for
detecting copy number variants. We have customers around the world
that have been leveraging the CytoScan Cytogenetics Suite and
OncoScan platforms for copy number analysis from different types of
cancer samples, and we’re pleased to be able to offer this joint
solution to help scientists to gain further insights into cancer
biology.”
For product and ordering information on the new Nexus Copy
Number for Affymetrix software, contact BioDiscovery, Inc.
PLEASE NOTE:
Affymetrix, the Affymetrix logo, OncoScan, and CytoScan are
trademarks of Affymetrix, Inc. All other trademarks and product
names are the property of their respective owners.
Affymetrix and BioDiscovery products mentioned in this release
are For Research Use Only. Not for use in diagnostic
procedures.
About BioDiscovery, Inc.
BioDiscovery Nexus Copy Number software offers simple yet
powerful tools for copy number (CNV) and sequence variation
analysis and visualization from microarrays and next generation
sequencing (NGS), for analysis of complex data such as solid tumor
samples and complex constitutional disease. The scientist-driven
software embeds powerful statistical tools designed specifically
for the end-user, allowing rapid detection of chromosomal
aberrations and identification of affected pathways.
BioDiscovery is a leader in the development of breakthrough
software and services for advanced copy number variation and
expression analysis, enabling customers in drug discovery,
research, and diagnostics by efficiently managing, integrating, and
analyzing data generated using high-throughput microarray and
next-generation sequencing technologies. For more information about
BioDiscovery, please visit www.biodiscovery.com.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness. The
Company provides leadership and support, partnering with customers
in pharmaceutical, diagnostic, and biotechnology companies, as well
as leading academic, government, and non-profit research institutes
in their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
65,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, Ohio,
San Diego, Vienna, and Singapore. The Company has about 1,100
employees worldwide and maintains sales
and distribution operations across Europe, Asia, and
Latin America. For more information about Affymetrix, please
visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2013, and other SEC reports for subsequent
quarterly periods.
AffymetrixMedia Contact:Mindy Lee-Olsen, 408-731-5523Vice
President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestor Contact:Doug
Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.comorBioDiscovery Inc.Media
Contact:Louis J. Culot, 617-233-4921Vice President, Business
Development and Marketing
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024